ライフサイエンスコーパス: drug level

1 nalysis (P=0.199, adjusted for age and serum drug level).

2 ificantly less likely to be tested for serum drug level.

3 were also less likely to be tested for serum drug level.

4 ategies to predict risk at an individual and drug level.

5 r therapeutic drug monitoring to control the drug level.

6 cess more robustly than constant, maintained drug levels.

7 ip between the kappa K(i) and the free brain drug levels.

8 drug dose adjustments were informed by serum drug levels.

9 to body weight, equalizing blood and tissue drug levels.

10 retina was used as a measure of the systemic drug levels.

11 reat to transplant recipients and may affect drug levels.

12 e more rapid dissolution and higher vitreous drug levels.

13 esponse, serving as drug targets and setting drug levels.

14 utilization was also impaired at comparable drug levels.

15 ide nano- and microparticles sustain retinal drug levels.

16 on correlated highly with steady-state brain drug levels.

17 toring plasma parameters such as viremia and drug levels.

18 with greater drug released based on residual drug levels.

19 on any other samples to assess on-treatment drug levels.

20 NFa, regardless of administration timing and drug levels.

21 pha, regardless of administration timing and drug levels.

22 fy the potential mechanisms behind these low drug levels.

23 in inhibitory activity because of inadequate drug levels.

24 based antiretroviral therapy with detectable drug levels.

25 was associated with undetectable adalimumab drug levels.

26 oviding elevated and sustained intracellular drug levels.

27 ing high-precision control over intracranial drug levels.

28 nt are underlying disease and subtherapeutic drug levels.

29 s no significant effect of IVM on DEC or ALB drug levels.

30 cation relative to sex significantly impacts drug levels.

31 antigenemia, adverse events (AEs), and serum drug levels.

32 cing, only 1 of which had low but detectable drug levels.

33 fects with respect to quantification of free drug levels.

34 e infant was reported to develop therapeutic drug levels.

35 sed over time and correlated with the plasma drug levels.

36 e less sensitive and may be normal at trough drug levels.

37 ssociated with poor adherence and low plasma drug levels.

38 F IVRs generated reproducible and protective drug levels.

39 cyclosporine implant produced lacrimal gland drug levels 1 to 2 log units higher than those reported

40 This change in drug levels (15% reduction) was made in an attempt to re

41 lated from Donor cells contained appreciable drug levels (2-7pmole/10(6) cells after 24h treatment wi

42 ized probabilities of response for any given drug level: a minimally effective drug level of 3.2 mug/

43 cal response was associated with a threshold drug level above 2.7 mug/mL or an antibody level below 1

44 a by day 28 in the CQ arm were noted to have drug levels above 100 ng/ml.

45 heoretical advantage of maintaining constant drug levels above a threshold known from preclinical dat

46 s, allowing cells to grow in the presence of drug levels above minimal inhibitory concentrations.

47 . in vivo Abeta42 lowering in mice occurs at drug levels achievable in humans, and (d). there is a si

48 s observed in U87MG gliomas, consistent with drug levels achieved.

49 one of 7 patients (35%) with subquantifiable drug levels after 12 weeks of therapy maintained respons

50 atient's immunosuppressive therapy; however, drug levels alone may not reflect the patient's immune s

51 We measured SP-AQ drug levels among SMC-eligible children and SP-AQ resist

52 eeks of surgery, and serum was collected for drug-level analyses.

53 r infliximab and underwent testing for serum drug level and ADAs at the National Eye Institute from S

54 nt assays were used to measure pembrolizumab drug level and ADAs in 41 patients with melanoma at base

55 al firing pattern closely mirrors changes in drug level and dopamine overflow observed by previous re

56 by a lack of consistent correlation between drug level and enzyme activity, particularly with chroni

57 In patients with recurrent parasitemia, drug level and genotyping using microsatellite markers w

58 f patients displayed a falling pembrolizumab drug level and rising ADA titre between Timepoint 1 and

59 piperazine substituent allowed for excellent drug levels and a long duration of action in the central

60 We found no correlation between trough drug levels and active TGFbeta1 levels in serum of eithe

61 Pembrolizumab drug levels and ADAs can be readily measured.

62 The main outcome was the association between drug levels and ADAs, clinical response, and concurrent

63 In proactive TDM, serum drug levels and anti-drug antibodies are measured irresp

64 ments based on scheduled monitoring of serum drug levels and antidrug antibodies (TDM group; n = 207)

65 ments based on scheduled monitoring of serum drug levels and antidrug antibodies (TDM group; n = 228)

66 substrate drugs may be at risk of increased drug levels and associated toxicity.

67 armacokinetic data confirmed that the plasma drug levels and clearance rates were similar for patient

68 More information on the relationship between drug levels and clinical outcomes is needed.

69 ction, confound the association between NOAC drug levels and clinical outcomes.

70 NP-470 schedules that produce more prolonged drug levels and clinical trial end points other than obj

71 onse is measured by monitoring pharmacologic drug levels and clinical/pathologic evaluation of graft

72 nalyzed in order to calculate average infant drug levels and determine what factors influence plasma

73 Measurement of circulating drug levels and development of ADAs in the setting of an

74 boratory studies, imaging, and monitoring of drug levels and lung function.

75 r (R(2) = 0.89 to 1.00) over a wide range of drug levels and may be used for drug quantification.

76 ment of eGFRcys and eGFRcr, supratherapeutic drug levels and medication-related AEs occurred more com

77 nding of the role played by heterogeneity in drug levels and pathogen transport is crucial for attemp

78 more than twice as likely to lead to optimal drug levels and reduced the odds of seizure by 68% compa

79 th controlled AD and to relate this to serum drug levels and serum biomarkers.

80 o, OSU-T315 attains pharmacologically active drug levels and significantly prolongs survival in the T

81 f the polymeric prodrug maintained high lung drug levels and targeted an intracellular depot of cipro

82 Skin rash also correlated with drug levels and tended to decrease in severity over time

83 rong correlation between the ISF/circulating drug levels and the device's potential clinical use for

84 time that tumor cells are exposed to maximum drug levels and the drug penetration distance, compared

85 Anti-TNFa drug levels and vaccine responses did not affect anti-sp

86 Anti-TNFalpha drug levels and vaccine responses did not affect anti-sp

87 hy/tandem mass spectrometry of intracellular drug levels, and biochemical TKI dissociation studies.

88 , discusses methods to measure and interpret drug levels, and critically assesses the role of routine

89 o BCL-2 inhibitors by reducing intracellular drug levels, and high ABCC1 levels predicts poor respons

90 e presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with

91 an be accomplished without increased risk if drug levels are adequately monitored.

92 Increasing preoperative serum anti-TNFalpha drug levels are associated with adverse postoperative ou

93 cal drug delivery; however, sustained tissue drug levels are difficult to achieve with these techniqu

94 use of previous demonstrations that systemic drug levels are effective in preventing SIV infection.

95 lism, and limited clinical data suggest that drug levels are elevated.

96 e, methods to monitor sufficient circulating drug levels are essential.

97 The lower renal drug levels are in keeping with the profound difference

98 Crucially, drug levels are predictive of response 6 months later, w

99 consumption, until adequate anti-arrhythmic drug levels are reached to safely perform catheter ablat

100 Significant plasma drug levels are recorded up to a year following injectio

101 rally thought that high systemic and mucosal drug levels are sufficient for protection.

102 ereas glucokinase activity was unaffected at drug levels as high as 1 mmol/l.

103 The median pembrolizumab drug level at 3 weeks was 237 ng/uL and did not correlat

104 inetic models used plasma and intrapulmonary drug levels at 8 and 16 weeks.

105 the clinic to provide sustained therapeutic drug levels at a target site, and thereby reducing the f

106 BAT dosing resulted in drug levels at least as great as those in the absence of

107 s are overall antifungal use, subtherapeutic drug levels at sites of infection/colonization, drug seq

108 s, which yielded negligible tumor and plasma drug levels at the time of treatment with light.

109 dent fashion, with large increases in marrow drug levels beginning at 600 mg bid and with sustained l

110 id suspension injection, with retina-choroid drug levels being higher beginning at 0.25 hour.

111 used to compute odds ratios (ORs) comparing drug levels between cases and controls.

112 on reduces dramatically systemic circulating drug levels but leads to significantly higher tissue dru

113 lines were higher than clinically achievable drug levels by 1-37 times for melphalan, 1-9 times for c

114 Subtherapeutic drug levels can be caused by poor adherence to the drug

115 ecifically to the heart, wherein therapeutic drug levels can be maintained over time, is highly desir

116 in the highly compartmentalized human body, drug levels can vary substantially between different org

117 Drug level changes appeared to be partially tumor depend

118 g MAPs and 6 cm(2) for Neupro(R)), delivered drug levels comparable to Neupro(R), indicating higher e

119 was detected in the tumor regions with high drug levels compared to the tumor regions with low drug

120 een whether preoperative serum anti-TNFalpha drug levels correlate with postoperative morbidity.

121 60 hours into the DX-9065a infusion, plasma drug levels correlated strongly with anti-factor Xa acti

122 Using drug-level data in plasma and from 9 distinct pulmonary

123 r diclofenac sodium salt solution injection, drug levels declined rapidly with no drug levels detecta

124 ection, drug levels declined rapidly with no drug levels detectable after 24 hours in the vitreous hu

125 sign, we determined associations between SMC drug levels, drug resistance markers, and presentation w

126 nature and extent of changes in circulating drug levels due to the presense of food, and their possi

127 ining anemic HCV-infected patients on target drug levels during combination therapy.

128 X sustained aqueous humor and vitreous humor drug levels during the 24-hour study, with a t(1/2) of 9

129 Approximately half achieved protective drug levels during the monthly visits, but adherence dec

130 Detectable serum drug levels equivalent to effective in vitro drug levels

131 Drug level feedback in the first 3 months of PrEP use di

132 d limited power to detect a modest effect of drug level feedback on adherence, and there was limited

133 PrEP uptake, persistence, and the effect of drug level feedback on adherence.

134 month 9, four (5%) of 76 participants in the drug-level feedback arm had tenofovir diphosphate 700 fm

135 issue-focused counselling once per month or drug-level feedback counselling based on PrEP drug conce

136 traumatic brain injury leading to increased drug levels for an extended period of time after cooling

137 aded nanoparticles provided sustained ocular drug levels for at least 7 days after subconjunctival ad

138 te rapid viremia suppression and therapeutic drug levels; for 10 months, this virus remained R5 tropi

139 Although metformin is renally cleared, drug levels generally remain within the therapeutic rang

140 s drawn at baseline, 4 and 8 weeks for blood drug levels, genome-wide single nucleotide polymorphism

141 SAR 1118 ophthalmic drops delivered retinal drug levels greater than 1 muM in less than 30 minutes a

142 sts, dose adjustment informed by circulating drug levels has been proposed.

143 ence and association with serum posaconazole drug levels has not previously been investigated.

144 ment based on scheduled assessments of serum drug levels, has been proposed as an alternative to stan

145 osing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to stan

146 ence and association with serum posaconazole drug levels have not previously been investigated.

147 To maintain serum drug levels, however, 21% higher doses of the extended-r

148 anism to account for variability in systemic drug levels; however, declining systemic sorafenib level

149 of a drug is a function of the intracellular drug level in a critical compartment.

150 Information is lacking on the optimal drug level in particular patient groups (eg, elderly, th

151 The mean (SD) drug level in the infliximab group was 27.02 (18.15) mug

152 Plasma drug levels in 26 individuals indicated PrEP use during

153 revealed that despite similar intracellular drug levels in 2D and 3D A549 cells during lapatinib tre

154 ations by clinical assays despite detectable drug levels in 8 participants.

155 didates needs to move beyond measurements of drug levels in blood, whole lungs, or alveolar epithelia

156 and determine what factors influence plasma drug levels in breast-feeding infants of mothers treated

157 These results were obtained despite drug levels in cerebrospinal fluid (CSF) that predict cl

158 d there is a tremendous variability in serum drug levels in children.

159 human skin and HPLC was used to analyze the drug levels in different skin layers.

160 s and their effect on adherence, assessed by drug levels in dried blood spots tested monthly for the

161 iously described isoxazoles, yielding higher drug levels in human cancer cells and xenografts.

162 monstrated 4.8-, 15.7-, and 2.1-fold greater drug levels in lung, bronchoalveolar lavage fluid (BAL),

163 g monitoring (TDM), which involves measuring drug levels in patients' body fluids, is an important pr

164 347-treated mice readily achieve therapeutic drug levels in peripheral blood.

165 l pharmacokinetic studies in mice, comparing drug levels in spleen to plasma, we selected compounds t

166 By direct measurement of drug levels in the blood, adherence rates to oral cortic

167 ad and that one compound achieved measurable drug levels in the brain.

168 s that impede the achievement of appropriate drug levels in the central nervous system.

169 due to their inability to achieve sufficient drug levels in the CNS.

170 ulature is further suggested by the elevated drug levels in the coronary sinus effluent.

171 two rodent species with significantly higher drug levels in the epithelial lining fluid of infected l

172 approach to achieving sustained, therapeutic drug levels in the eye.

173 ma and tissue stability to achieve increased drug levels in the liver.

174 ing doses of rifampicin resulted in elevated drug levels in the livers of mdr1a (-/-) mice compared w

175 ct correlation between the pore size and the drug levels in the living eye vitreous was confirmed.

176 ith AMB-NIV resulted in significantly higher drug levels in the lungs and skin (p<0.05) compared to s

177 e correlation of clinical effects with brain drug levels in the paroxetine group suggests that relati

178 tic drug monitoring (TDM) involves measuring drug levels in the patient bloodstream to ensure optimal

179 Drug levels in the perfusate were analysed using ultra-h

180 reast cancer (200 mg/d) achieved only modest drug levels in the prostate and is unlikely to be effect

181 sustained in vitro drug release and in vivo drug levels in the retina for 60 days.

182 ivally to one eye of Sprague-Dawley rats and drug levels in the retina, vitreous, lens, and cornea of

183 Higher detectable drug levels in the retina-choroid suggest rapid settling

184 seizure disorder, with stable anticonvulsant drug levels in the upper half of the therapeutic range,

185 ose of diclofenac sodium solution to sustain drug levels in the vitreous beyond 11 days.

186 Whole-brain drug levels in this group were compared to similarly acq

187 When drug levels in tumors relative to plasma were examined,

188 Drug levels in various ocular tissues were analyzed by l

189 Maintaining safe and potent drug levels in vivo is challenging.

190 Comparisons among reported serum drug levels indicate that new fluoroquinolones are the l

191 They regulate systemic and cellular drug levels influencing efficacy as well as toxicities.

192 ment response, highlighting the need to take drug levels into account when searching for biomarkers o

193 t of the mechanism that transduces declining drug levels into increased drug-related appetitive behav

194 oor correlation between clinical effects and drug levels likely accounts for this finding.

195 %) not achieving PASI 75 had subquantifiable drug levels (<0.05 mug/mL), although this finding was se

196 icity or systemic side effects with very low drug levels measured in the aqueous, vitreous, and serum

197 Drug levels measured over the same time course as that u

198 dy provides class A evidence that systematic drug level monitoring of newer generation AEDs does not

199 novo sirolimus requires careful therapeutic drug level monitoring, especially the first 6 months pos

200 any given drug level: a minimally effective drug level of 3.2 mug/ml discriminates responders (PASI7

201 Drug levels of 17-AAG were determined by high-performanc

202 Data suggest that equivalent plasma drug levels of acyclovir can be achieved after administr

203 studies that reported a relationship between drug levels of dabigatran, rivaroxaban, and apixaban and

204 All cases displayed low drug levels of either CAB, RPV, or both during the treat

205 3.0 ug/mL, significantly lower than the mean drug levels of patients without AAA (11.8 ug/mL).

206 ociation between CYP2C19/CYP2D6 genotype and drug levels of several psychiatric drugs was quantified

207 y because of a direct effect of dopaminergic drug level on reward sensitivity.

208 itumor necrosis factor-alpha (anti-TNFalpha) drug levels on 30-day postoperative morbidity in inflamm

209 evaluated the impact of antimicrobial plasma drug levels on time-to-positivity (TTP) trajectories in

210 ated short IV infusion schedule, daily serum drug levels only briefly exceeded concentrations necessa

211 Subgroup analyses indicate that plasma drug levels or anticoagulant activity of the NOACs predi

212 Drug levels or doses were recorded during the 3 months b

213 mates failed to substantially elevate plasma drug levels or to reduce the development of grade IV CNV

214 er than severe injury, fail to examine brain drug levels or treatment optimization, and do not use an

215 lar fluid samples were used to monitor daily drug levels over 7 days, while clinical responses were a

216 I, -0.01 to -0.34 mug/mL) difference in mean drug level (P < .001).

217 interval, .16-.67]; P = .002) and have lower drug levels (P < .05).

218 evels compared to the tumor regions with low drug levels (p < 0.05).

219 , and lesions in the presence of therapeutic drug levels (P=.11) were more likely to occur with CsA t

220 n procedures resulting in repeatedly spiking drug levels produce more robust increases in Pmax than p

221 s levels significantly correlated with serum drug levels, providing further evidence for the efficacy

222 regating these incremental costs to estimate drug-level R&D costs per new drug.

223 hallenge assay measuring plasma nitrates and drug levels, rapidly led to the identification of compou

224 The portal-to-systemic drug level ratio ranged from 0.95 to 2.71 for sirolimus

225 Drug levels reached 6 mug/10(6) cells in human monocyte-

226 possibly methotrexate can increase anti-TNF drug levels, reduce the risk of antidrug antibodies, and

227 of the neurophysiological mechanism by which drug level regulates drug-taking behavior during an ongo

228 significant age effects on brain fluoxetine drug levels remained after adjustment for dose/mass.

229 lerance was sufficiently short that the high drug levels required might be expected to be tolerated c

230 and EPSP slope by 58+/-7% and 31+/-6% of pre-drug levels, respectively.

231 s 81% (95% CI = 76-86); beyond 7 mug/ml, the drug level/response curve plateaus.

232 Low drug levels resulting from oral GCV therapy may predispo

233 This real-world study with pragmatic drug level sampling provides evidence to support the pro

234 e or in combination with AZT or D4T, even at drug levels severalfold higher than those used in the vi

235 ot inhibit platelet thromboxane B2 at plasma drug levels similar to those obtained in early clinical

236 1 X d-1) in the study animals yielded plasma drug levels sufficient either to chronically block or, f

237 sorder diagnoses did not receive therapeutic drug level testing during the 12-month study period.

238 Serum drug level testing with reflex testing for ADA levels wa

239 e utilization were related to rates of serum drug level testing.

240 med with dried blood spot and segmental hair drug-level testing and single-genome sequencing.

241 1 and 7 days after viral exposure, elicited drug levels that paralleled the human median effective c

242 Cells accumulated intracellular drug levels that were at least 8-fold higher than extrac

243 CAB and RPV drug levels that were below the first quartile of the po

244 At intermediate drug levels the spectrum narrowed to F317V and T315I for

245 Intravitreal drug levels, the amount of drug remaining in explanted d

246 were observed at or near clinically relevant drug levels, they preceded lethal injury, and they corre

247 We confirm serum drug level to be the most important factor determining t

248 acts as capacitive space for drug and shifts drug levels to decrease tissue uptake 2-fold.

249 vity, while systemic delivery of therapeutic drug levels to the brain tumour is limited by the blood-

250 g dosing is adjusted to achieve target serum drug levels, usually within pre-specified therapeutic ra

251 is the main determinant of immunosuppressive drug level variability.

252 Plasma drug levels varied considerably between subjects and dec

253 nto the peritoneal cavity, enabling elevated drug levels versus intravenous (i.v.) injection.

254 tumor exposure to therapeutically effective drug levels via reversible conjugation to Pluronic F-108

255 sinophilia above baseline levels occurred as drug levels waned.

256 Tumor-to-plasma drug level was 1.0.

257 ; 170 [57.6%] men), the median (IQR [range]) drug level was 86.6 mug/mL (64.6-110.0 mug/mL [10.1-382.

258 In the adalimumab group, mean (SD) drug level was 9.72 (6.82) mug/mL, mean (SD) ADA level w

259 ably self-administer cocaine, the cumulative drug level was calculated during sessions in which cocai

260 Mean drug level was lower in those with ADAs compared with th

261 The vitreous drug level was then measured at different time points.

262 ncement Guided by Individualized Texting and Drug Levels was a 48-week, single-arm, open-label demons

263 Maintenance of therapeutic drug levels was associated with favorable results.

264 etween 2002 and 2003, the variation of serum drug levels was studied as a potential objective tool to

265 Patients who did receive tests for serum drug level were likely to receive the other recommended

266 drug levels equivalent to effective in vitro drug levels were achieved at the 20-, 30-, and 40-microg

267 eatment was discontinued once therapeutic CI drug levels were achieved.

268 Steady-state drug levels were associated with a 5-HT uptake inhibitio

269 The tumor regions containing high drug levels were associated with a higher degree of vasc

270 dolescence, underweight, and/or undetectable drug levels were at higher risk of failing second-line A

271 Hemolytic anemia recurred when drug levels were cleared from the circulation 3 to 4 wee

272 Serum drug levels were evaluated in a subset of patients.

273 Plasma drug levels were followed and outcome measures included

274 Drug levels were found to decline significantly over tim

275 Throughout the assessed time course, drug levels were higher in the vitreous.

276 Plasma drug levels were linear with dose.

277 Favipiravir drug levels were lower in the combination arm than the f

278 However, sustained, high drug levels were observed in both the vitreous humor and

279 ficant synergy was observed at physiological drug levels when PYR/SDX acted on purified DHFR, whether

280 ntitubercular drugs leads to variable plasma drug levels, which are associated with adverse drug reac

281 -HIV drug efavirenz activates CYP46A1 at low drug levels while inhibiting the enzyme activity at the

282 There was a higher mean drug level with concurrent antimetabolite use compared w

283 iation (aHR, 2.8; P = .03), and undetectable drug levels within 6 months following second-line initia

284 tacrolimus dosing more effectively maintains drug levels within the target range compared to SOC, sug

285 gh it is possible to accurately measure NOAC drug levels, within-patient variability complicates inte

286 and the resultant achievement of high plasma drug levels without associated nausea or emesis.

287 red, although reduced toxicity and sustained drug levels would be anticipated to improve systemic bio